Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin (Q36134463)

12 August 2017

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin (English)

1 reference

12 August 2017

1 reference

Matsui K

1

1 reference

12 August 2017

Fukuoka M

2

1 reference

12 August 2017

Takada M

3

1 reference

12 August 2017

Kusunoki Y

4

1 reference

12 August 2017

Yana T

5

1 reference

12 August 2017

Tamura K

6

1 reference

12 August 2017

Yoshida T

7

1 reference

12 August 2017

Iida K

8

1 reference

12 August 2017

Hirashima T

9

1 reference

12 August 2017

Tsukada H

10

1 reference

12 August 2017

Ushijima S

11

1 reference

12 August 2017

Miyawaki H

12

1 reference

12 August 2017

Masuda N

13

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

73

1 reference

12 August 2017

2

1 reference

12 August 2017

217-221

1 reference

The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Toxic effects of cis-dichlorodiammineplatinum(II) in man.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074303

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients

23 September 2018

1 reference

12 December 2020

5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study

1 reference

12 December 2020

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Extrapyramidal reactions with high-dose metoclopramide

1 reference

12 December 2020

PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST

1 reference

12 December 2020

Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors

1 reference

12 December 2020

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

12 December 2020

Acute and Delayed Emesis after Cisplatin-Based Regimen: Description and Prevention

1 reference

12 December 2020

Who should receive a 5-HT3 antagonist?

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1996.38

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference

12 August 2017

PubMed publication ID

8546909

1 reference